Mark Shackleton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6067773/publications.pdf

Version: 2024-02-01

26 papers 5,499 citations

471509 17 h-index

26 g-index

552781

29 all docs

29 docs citations

times ranked

29

10431 citing authors

#	Article	IF	CITATIONS
1	Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs. Cell Death and Disease, 2022, 13, 301.	6.3	1
2	Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (<scp>MelCOR</scp>): A modified Delphi study. Australasian Journal of Dermatology, 2022, , .	0.7	2
3	Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clinical Lung Cancer, 2021, 22, e425-e430.	2.6	15
4	Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review. BMJ Open, 2021, 11, e040751.	1.9	13
5	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature Communications, 2021, 12, 1434.	12.8	46
6	Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma. Clinical and Translational Radiation Oncology, 2021, 30, 95-99.	1.7	5
7	Reduced melanoma referrals during COVID-19 lockdown. Australian Journal of General Practice, 2021, 50, .	0.8	6
8	Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24 + CD29 CD49fhi in mice. Breast Cancer Research and Treatment, 2020, 183, 565-575.	2.5	4
9	Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2020, 108, 150-156.	0.8	11
10	The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis. Oncogene, 2020, 39, 5267-5281.	5.9	53
11	Somatic Hypermutation of the <i>YAP</i> Oncogene in a Human Cutaneous Melanoma. Molecular Cancer Research, 2019, 17, 1435-1449.	3.4	39
12	Bevacizumab as a steroidâ€sparing agent during immunotherapy for melanoma brain metastases: A case series. Health Science Reports, 2019, 2, e115.	1.5	29
13	Personalised surveillance after treatment for high-risk cancer. Oncotarget, 2019, 10, 694-695.	1.8	2
14	Whole-genome landscapes of major melanoma subtypes. Nature, 2017, 545, 175-180.	27.8	1,068
15	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-14.	3.0	51
16	A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology, 2016, 34, 1010-1014.	17.5	66
17	Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications, 2016, 7, 12336.	12.8	43
18	CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. Cancer Research, 2016, 76, 3965-3977.	0.9	26

#	Article	IF	CITATIONS
19	Postâ€operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of preâ€operative treatment and elective indication. Journal of Surgical Oncology, 2015, 111, 980-984.	1.7	24
20	Whole–genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	27.8	1,206
21	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 2015, 75, 5228-5234.	0.9	270
22	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Science Signaling, 2015, 8, ra82.	3.6	114
23	Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. Bioinformatics, 2014, 30, 1064-1072.	4.1	75
24	Human Melanoma Metastasis in NSG Mice Correlates with Clinical Outcome in Patients. Science Translational Medicine, 2012, 4, 159ra149.	12.4	98
25	Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized. Cancer Cell, 2010, 18, 510-523.	16.8	555
26	Efficient tumour formation by single human melanoma cells. Nature, 2008, 456, 593-598.	27.8	1,674